FHD-609 in Subjects With Advanced Synovial Sarcoma
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to
assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and
preliminary clinical activity of FHD-609 given intravenously in subjects with advanced
synovial sarcoma.